SILVER SPRING, Md., Feb. 16, 2024 /PRNewswire/ — Today, the U.S. Food and Drug Administration approved Xolair (omalizumab) injection for immunoglobulin E-mediated food allergy in certain adults and children 1 year or older for the reduction of allergic reactions (Type I), including…
FDA Approves First Medication to Help Reduce Allergic Reactions to Multiple Foods After Accidental Exposure
This post was originally published on this site